IMNM - Immunome Inc
NYSE * Health Care * Biotechnology
$22.61
+$0.94 (+4.36%)
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Key Statistics
Market Cap
$2.45B
P/B Ratio
3.86
EPS
$-2.43
Revenue Growth
-1.0%
Employees
177
How IMNM Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Immunome Inc Company Information
- Headquarters
- Pennsylvania; U.S.A
- Website
- immunome.com
- Sector
- Health Care
- Industry
- Biotechnology